🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Kinase Degraders, Activators, and Inhibitors: Highlights and Synthesis Routes to the Chemical Probes on opnMe.com, Part 1 (Gollner) Andreas Gollner; Boehringer Ingelheim #openaccess onlinelibrary.wiley.com/doi/10.1002/cm…

We are excited to announce a new ADAR1 focused drug discovery collaboration with leading pharma company Boehringer Ingelheim. Boehringer Ingelheim Roivant Sciences globenewswire.com/news-release/2…

Looking forward to work together and join forces with the Covant Tx team on an exciting IO-target.

Our new collaboration with Covant Tx aims to develop a novel small molecule cancer immunotherapy to turn "cold" tumors "hot" by inhibiting ADAR1, a regulator of the innate immune system. Learn more: bit.ly/3zjCaGp #CancerImmunoTherapy #Cancer #ResearchAndDevelopment

We are excited to announce a new ADAR1 focused drug discovery collaboration with leading pharma company Boehringer Ingelheim. Boehringer Ingelheim Roivant Sciences

#AACR23 Check out the first disclosure of our MDM2-p53 antagonist BI 907828 currently in clinical trials. A tour de force in medicinal chemistry. Presented at 1.30 pm, poster LB003, section 34 by Harald Weinstabl #MDM2 #DDLPS Andreas Gollner Darryl B McConnell P. Sini and D. Rudolph

So excited to share CysDB in its final form, now published in CellChemicalBiology authors.elsevier.com/a/1g%7Ev68jWWJ…

Why inhibit only one KRAS mutant when you can inhibit multiple KRAS alterations at the same time. Our pan-KRAS inhibitor paper is out. nature.com/articles/s4158…

Proud of our SR contributions on the different KRAS mutants by @BoettcherJark and Wolkerstorfer. Some structures in world record time from soaking to final publication ready structure in <24h!

Thrilled to share that our paper on Pan-KRAS inhibitors is now live nature. Inhibitors prevent activation of WT and a broad range of #KRAS mutants, while sparing HRAS+NRAS. Congrats to collaborators @boehringer and MSKCC. #PrecisionOncology OncoAlert nature.com/articles/s4158…

Our MDM2-p53 antagonist showed a manageable safety profile and encouraging signs of efficacy in this Cancer Discovery publication from an open-label, first-in-human, Phase Ia/Ib study in people with advanced solid tumors and MDM2 amplification. Further investigations are ongoing. #ASCO23

Nice summary of our achievements on panKRAS inhibition: Taking down KRAS cen.acs.org/pharmaceutical… via C&EN (Chemical & Engineering News) Darryl B McConnell Norbert Kraut

We are looking for collaboration partners! Please submit your proposals for promising tumor-specific genetic dependencies here: opnme.com/opn2experts/cr…

Happy to be part of a multi-institutional effort through an academia-industry partnership in the systematic analysis of the WWE domain in human E3 ligases using our PAR labeling technology! nature.com/articles/s4200… Structural Genomics Consortium (SGC) Boehringer Ingelheim Johns Hopkins BMB University of Oxford University of Toronto

🧰A versatile toolbox of biophysical and biochemical assays for the discovery of novel ligands of tryptophan-tryptophan-glutamate domain-containing proteins: doi.org/10.1038/s42003…

Screening in medicinal chemistry just got smarter! Our MIIS tool to combat metal interference false positives. Read in #JMedChem. go.acs.org/ait

Passionate about structural biology and biochemistry? Join David Haselbach’s group through the Vienna BioCenter #PhD Program (Vienna BioCenter Scientific Training)! ⏳ Deadline: October 15 Apply now: training.vbc.ac.at/phd-program/ 📽️Watch David's 'Scientist Snapshot': youtube.com/watch?v=DXTOW3…